Consolidation chemotherapy with capecitabine after neoadjuvant chemoradiotherapy in high-risk patients with locally advanced rectal cancer: Propensity score study

Table 2 The clinical parameters between the two groups after propensity score match and inverse probability of treatment weighting

	PSM			IPTW
	non-CC group (n = 105)	CC-group (n = 105)	P value	non-CC group (n = 130)	CC-group (n = 135)	P value
Gender, n (%)			0.762			0.970
Male	75 (71.4)	73 (69.5)		89.4 (68.5)	92.6 (68.7)
Female	30 (28.6)	32 (30.5)		41.1 (31.5)	42.2 (31.3)
Age			0.692			0.993
mean (SD)	57.7 (11.8)	58.3 (9.7)		58.2 (11.2)	58.2 (9.7)
Primary location, n (%)			0.849			0.996
Up	3 (2.9)	2 (1.9)		4.9 (3.8)	4.9 (3.7)
Middle	52 (49.5)	50 (47.6)		61.0 (46.7)	63.8 (47.3)
Low	50 (47.6)	53 (50.5)		64.6 (49.5)	66.1 (49.0)
Pathology, n (%)			0.903			0.999
Well-differentiated	5 (4.8)	5 (4.8)		6.3 (4.9)	6.6 (4.9)
Moderately-differentiated	79 (75.2)	75 (71.4)		94.0 (72.0)	97.9 (72.6)
Poorly-differentiated	12 (11.4)	13 (12.4)		16.6 (12.7)	17.0 (12.6)
Others	9 (8.6)	12 (11.4)		13.6 (10.4)	13.3 (9.9)
CEA, n (%)			0.428			0.997
Normal	51 (48.6)	58 (55.2)		64.1 (49.1)	66.8 (49.5)
Unnormal	45 (42.9)	42 (40.0)		55.2 (42.3)	56.7 (42.1)
unidentified	9 (8.6)	5 (4.8)		11.2 (8.6)	11.3 (8.4)
T stage, n (%)			0.568			0.992
< T3c	41 (39.0)	37 (35.2)		48.0 (36.8)	49.7 (36.9)
> T3b	64 (61.0)	68 (64.8)		82.5 (63.2)	85.1 (63.1)
N stage, n (%)			0.097			0.176
N0	10 (9.5)	4 (3.8)		12.1 (9.3)	6.7 (5.0)
N+	95 (90.5)	101 (96.2)		118.4 (90.7)	128.1 (95.0)
Tumor length (mm)			0.916			0.983
mean (SD)	48.6 (13.0)	48.4 (13.2)		48.9 (12.5)	48.9 (13.5)
Tumor thickness (mm)			0.484			0.999
mean (SD)	16.6 (5.0)	16.0 (7.0)		16.4 (4.9)	16.4 (7.2)
MRF, n (%)			> 0.99			0.865
Negative	23 (21.9)	23 (21.9)		29.7 (22.8)	29.5 (21.9)
Positive	82 (78.1)	82 (78.1)		100.7 (77.2)	105.3 (78.1)
EMVI, n (%)			0.771			0.998
Negative	35 (33.3)	37 (35.2)		46.4 (35.6)	48.0 (35.6)
Positive	70 (66.7)	68 (64.8)		84.0 (64.4)	86.8 (64.4)
Numbers of high-risk factor, n (%)			0.510			0.883
1	31 (29.5)	26 (24.8)		36.5 (28.0)	35.1 (26.0)
2	37 (35.2)	45 (42.9)		51.2 (39.2)	56.9 (42.2)
3	37 (35.2)	34 (32.4)		42.8 (32.8)	42.8 (31.7)
Interval time (d)			0.659			0.819
mean (SD)	74.4 (20.0)	75.6 (18.4)		75.5 (25.1)	74.8 (17.7)

PSM: Propensity score match; IPTW: Inverse probability of treatment weighting; CC: Consolidation chemotherapy; SD: Standard deviation; CEA: Carcinoembryonic antigen; MRF: Mesorectal fascia; EMVI: Extralmural venous invasion.